Composition for preventing or treating sars coronavirus 2 infection disease

Abstract

Disclosed is a pharmaceutical composition for preventing or treating severe acute respiratory syndrome coronavirus 2 infection disease, the composition comprising a compound represented by a Chemical Formula 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.

Description

technical field [0001] The present invention relates to a composition for preventing or treating severe acute respiratory syndrome coronavirus 2 infection or diseases caused by severe acute respiratory syndrome coronavirus 2 infection. Background technique [0002] Severe acute respiratory syndrome coronavirus 2 is also known as COVID-19, SARS-CoV-2, 2019-nCoV virus. The World Health Organization (WHO) declared a public health emergency of international concern (PHEIC) in response to COVID-19, and on March 11, 2020, declared COVID-19 as a follow-up to Hong Kong influenza (1968) and influenza A (H1N1) (2009). global pandemic. COVID-19 is transmitted when droplets (saliva) from an infected person penetrate the respiratory tract or the mucous membranes of the eyes, nose and mouth. And when infected, after an incubation period of 2 to 14 days (estimated), respiratory symptoms such as fever, cough or dyspnea, and main symptoms such as pneumonia will appear, but occasionally asy...

AI Technical Summary

Problems solved by technology

[0007] As technologies related to pharmaceutical compositions for improving or treating coronavirus infections, Korean Patent No. 1913789 discloses compounds for treating diseases caused by coronavirus infections, and U.S. Laid-Open Patent No. 2006-0257852 discloses Technology related to severe acute respiratory syndrome coronavirus, but does not disclose the composition of the present invention for preventing or treating coronavirus infection, which contains the activity inhibitor of coronavirus 3CL protease as an active ingredient

Images